NICE launches public consultation on changes for health technology evaluation

pharmafile | August 19, 2021 | News story | |   

NICE has launched a public consultation on proposed changes to the way it develops recommendations across its health technology evaluation programmes.

From today until 13 October 2021, NICE is seeking feedback on proposed changes to its health technology assessment methods, and processes.

The consultation is the culmination of the most wide-ranging and comprehensive review NICE has ever carried out, which has involved health system partners as well as industry, healthcare professionals, academia, and patients.

The goal of the proposals is to provide earlier access to valuable new innovative treatments; more equitable access to treatments for those with severe diseases; greater clarity and predictability of health technology assessment outcomes; enhanced flexibility in the use of a comprehensive evidence base, including use of real-world data; and support for the life sciences vision of making the UK a more attractive place for life sciences companies to succeed and grow.

Professor Gillian Leng CBE, NICE Chief Executive, said: “As NICE grows in importance for the health service in England, so do expectations from all our stakeholders for what our methods and processes can do for them.

“Chief among these is how we can reflect and enable the broader vision of the life sciences industry, patients, and the service for accelerated access to innovative health technologies while managing risk and ensuring the NHS gets value for money.

“Taken together, these proposals will bolster the ability of NICE to support access to valuable innovative technologies that bring health benefits for patients and good value to the NHS – staying robust, efficient, and future-proof to meet the challenges of advances in health technologies.”

Richard Torbett, Chief Executive of the Association of the British Pharmaceutical Industry, said: “This is a major milestone in an important review, and a significant opportunity to update the methods and processes NICE uses to support access to the life changing medicines of today and tomorrow.

“The ABPI and our members will be working hard over the coming months to help make sure the proposals meet the ambition of the UK’s Life Sciences Vision and deliver meaningful change for patients, their families, and the NHS.”

Lilly Subbotin

Related Content

No items found

Latest content